Fractyl Health, Inc. (GUTS)

NGM – Real vaqt narxi. Valyuta: USD

0.74

-0.06 (-7.00%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.75

+0.01 (0.94%)

Bozordan keyin: Jun 26, 2026, 7:33 PM EDT

04.06.2026

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure

01.06.2026

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced the appointment of Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy.

14.05.2026

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

13.05.2026

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

13.05.2026

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health NASDAQ: GUTS said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company's first-quarter 2026 earnings call.

12.05.2026

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month randomized data from the REMAIN-1 Pivotal Cohort and late Q4 2026 timing for potential FDA De Novo marketing application submission in post-GLP-1 weight maintenance reaffirmed Clinical Trial Application authorization of RJVA-001 first-in-human study in the Netherlands for T2D; first-in-human dosing anticipated in second half of 2026 reiterated Cash runway guidance into early 2027, beyond anticipated Pivotal data readout reiterated Conference call today at 4:30 p.m. ET BURLINGTON, Mass.

11.05.2026

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 diabetes

Videolar

No Data

There is no data to display

Press-relizlar

04.06.2026

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure

01.06.2026

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

12.05.2026

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

11.05.2026

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health, Inc. (GUTS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Fractyl Health, Inc. (GUTS)

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Videolar

No Data

Press-relizlar

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Videolar

No Data

Press-relizlar

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Search stocks

Fractyl Health, Inc. (GUTS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Fractyl Health, Inc. (GUTS)

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Videolar

No Data

Press-relizlar

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Videolar

No Data

Press-relizlar

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes